Latest Financial Results
Q3 2022
Quarter Ended Sep 30, 2022
$317M
Total revenue of $317.0 million, up 40% from $227.1 million for the prior-year quarter$26M
Net income attributable to ApolloMed of $26.0 million, compared to $34.3 million for the prior-year quarter$0.56
Earnings per share - diluted ("EPS - diluted") of $0.56, compared to $0.74 per share for the prior-year quarterFor complete information regarding our financials, see our periodic filings